Taiwan · Delayed Price · Currency is TWD Anya Biopharm Statistics
Total Valuation
Anya Biopharm has a market cap or net worth of TWD 1.60 billion. The enterprise value is 1.28 billion.
| Market Cap | 1.60B |
| Enterprise Value | 1.28B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Anya Biopharm has 49.10 million shares outstanding. The number of shares has decreased by -0.27% in one year.
| Current Share Class | 49.10M |
| Shares Outstanding | 49.10M |
| Shares Change (YoY) | -0.27% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 21.45% |
| Owned by Institutions (%) | 5.38% |
| Float | 30.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 122.18 |
| PB Ratio | 4.57 |
| P/TBV Ratio | 4.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 98.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 67.66, with a Debt / Equity ratio of 0.01.
| Current Ratio | 67.66 |
| Quick Ratio | 64.91 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -180.75 |
Financial Efficiency
Return on equity (ROE) is -13.14% and return on invested capital (ROIC) is -15.13%.
| Return on Equity (ROE) | -13.14% |
| Return on Assets (ROA) | -14.84% |
| Return on Invested Capital (ROIC) | -15.13% |
| Return on Capital Employed (ROCE) | -25.89% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Anya Biopharm has paid 1.92 million in taxes.
| Income Tax | 1.92M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.14% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -49.14% |
| 50-Day Moving Average | 30.81 |
| 200-Day Moving Average | 34.34 |
| Relative Strength Index (RSI) | 48.86 |
| Average Volume (20 Days) | 41,609 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Anya Biopharm had revenue of TWD 13.06 million and -49.13 million in losses. Loss per share was -1.00.
| Revenue | 13.06M |
| Gross Profit | 12.92M |
| Operating Income | -91.28M |
| Pretax Income | -47.20M |
| Net Income | -49.13M |
| EBITDA | -89.76M |
| EBIT | -91.28M |
| Loss Per Share | -1.00 |
Balance Sheet
The company has 317.30 million in cash and 3.52 million in debt, with a net cash position of 313.78 million or 6.39 per share.
| Cash & Cash Equivalents | 317.30M |
| Total Debt | 3.52M |
| Net Cash | 313.78M |
| Net Cash Per Share | 6.39 |
| Equity (Book Value) | 349.36M |
| Book Value Per Share | 7.11 |
| Working Capital | 330.45M |
Cash Flow
In the last 12 months, operating cash flow was -75.57 million and capital expenditures -835,000, giving a free cash flow of -76.40 million.
| Operating Cash Flow | -75.57M |
| Capital Expenditures | -835,000 |
| Depreciation & Amortization | 1.52M |
| Net Borrowing | -129,000 |
| Free Cash Flow | -76.40M |
| FCF Per Share | -1.56 |
Margins
| Gross Margin | 98.91% |
| Operating Margin | -698.86% |
| Pretax Margin | -361.38% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Anya Biopharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.27% |
| Shareholder Yield | 0.27% |
| Earnings Yield | -3.08% |
| FCF Yield | -4.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Anya Biopharm has an Altman Z-Score of 142.76 and a Piotroski F-Score of 1.
| Altman Z-Score | 142.76 |
| Piotroski F-Score | 1 |